

## StAmP

A Proof of Principle, Double-Blind, Randomised, Placebo-Controlled, Multi Centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia.

### StAmP trial objectives:

The aim of this trial is to establish whether pravastatin causes a significant reduction of circulating anti-angiogenic factors in women with early-onset pre-eclampsia. To answer this hypothesis, we will ask the following:

1. Does pravastain, compared with placebo, inhibit anti-angiogenic factors in women with early-onset pre-eclampsia?
2. If this principle is established, how best can a substantive trial/ health technology assessment be undertaken to develop guidance for routine use of statins in pre-eclampsia?
3. Are there any adverse effects to the mother or the baby following gestational exposure to pravastatin?

---

**EudraCT Number:** 2009-012968-13

**ISRCTN Number:** 23410175

**Funder:** Medical Research Council

**Grant Holder:** Professor Asif Ahmed, Aston University

**Sponsor:** University College London

**Chief Clinical Investigator:** Dr David Williams

**Trial Coordinating Centre:** Birmingham Clinical Trials Unit, University of Birmingham

---

[Privacy](#) | [Legal](#) | [Cookies and cookie policy](#) | [Accessibility](#) | [Site map](#) | [Website feedback](#) | [Charitable information](#)

© University of Birmingham 2015

